Clinical Trials Logo

Hyperlipidemia clinical trials

View clinical trials related to Hyperlipidemia.

Filter by:

NCT ID: NCT04438096 Recruiting - Hyperlipidemia Clinical Trials

Safety and Efficacy of CVI-LM001 in Patients With Hypercholesterolemia

Start date: July 15, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if CVI-LM001 is effective and safe versus placebo in drug-naive subjects with elevated LDL cholesterol. There will be 4 groups receiving 100mg, 200mg, 300 mg and placebo treatment for 12 weeks respectively.

NCT ID: NCT03862183 Recruiting - Hypertension Clinical Trials

Hospital-level Variation in the Management of Blood Pressure and Low-density Lipoprotein in the Outpatient Hypertensives in China-a Cross Sectional Study

Start date: July 1, 2017
Phase:
Study type: Observational [Patient Registry]

To investigate the proportion, medication use and control rate of metabolic abnormalities such as dyslipidemia in outpatients with hypertension in different levels of hospitals in China. To investigate the gap between guidelines and clinical practices, and analyze the cause. we also set up a continuing medical education program to narrow the gap and the effect of the program will be estimated.

NCT ID: NCT02979704 Recruiting - Hyperlipidemia Clinical Trials

A Comparative Study of Rosuvastatin and Atorvastatin in Patients With Hyperlipidemia

Start date: September 2016
Phase: Phase 2/Phase 3
Study type: Interventional

This study will be conducted to assess the status of oxidative stress inflammation and thrombogenesis in patients with hyperlipidemia and to compare the antioxidative, anti-inflammatory and antithrombogenic effects of rosuvastatin and atorvastatin.

NCT ID: NCT02262832 Recruiting - Diabetes Clinical Trials

Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy

Start date: October 9, 2014
Phase: Phase 3
Study type: Interventional

Background: - Generalized lipodystrophy can cause high blood fat levels and resistance to insulin. This can lead to health problems including diabetes. Researchers have found that the drug metreleptin improves health in people with this disease. Objective: - To test the safety and effectiveness of metreleptin. Eligibility: - People ages 6 months and older with generalized lipodystrophy who: - have received metreleptin through NIH studies AND - cannot get it through approved or compassionate use mechanisms in their home country. Design: - Participants will come to NIH approximately every 6 months during year one, then every 1 2 years. Financial assistance may be available for travel within the U.S. - At visits, participants will get a supply of metreleptin to take home for daily injections. They will have: - plastic catheter placed in an arm vein. - blood tests, urine collection, and physical exam. - oral glucose tolerance test, drinking a sweet liquid. - ultrasound of the heart, liver, uterus, and ovaries. A gel and a probe are placed on the skin and pictures are taken of the organs. - echocardiogram, which takes pictures of the heart with sound waves. - Resting Metabolic Rate taken. A plastic hood is worn over the head while the oxygen they breathe is measured. - Participants will have up to 3 DEXA scan x-rays per year. - Participants may have: - annual bone x-rays. - liver biopsies every few years. A needle will be inserted into the liver to obtain a small piece. Participants will sign a separate consent for this. - Participants must be seen regularly by their local doctors and have blood tests at least every 3 6 months at home.

NCT ID: NCT02087540 Recruiting - Hypertension Clinical Trials

Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia

Start date: May 2013
Phase: Phase 3
Study type: Interventional

To identify efficacy and safety of Telmisartan/Rosuvastatin co-administration in hyperlipidemia control in hypertensive patients with hyperlipidemia compared to each monotherapy.

NCT ID: NCT01890889 Recruiting - Hyperlipidemia Clinical Trials

Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health

AdBiotech
Start date: July 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effectiveness of a food-source nutrient containing bitter orange by comparing changes 45 blood chemistries and self-reported quality of life.

NCT ID: NCT01752803 Recruiting - Obesity Clinical Trials

RCT Examining Effects of Probiotics in T2DM Individuals

Start date: December 2012
Phase: N/A
Study type: Interventional

Background: The connection between gut health and diabetes status is increasingly recognized. Gut microbiota composition in diabetic differs from non-diabetic individuals. Interestingly, the level of glucose tolerance was associated with specific microbiota that was rarely found in healthy individuals. Probiotics is one of the functional foods believed to mediate their health promoting activities through modulating the composition of the gut health. Ingestion of probiotics has been shown not only to influence gut microbiota composition but also the secretion of the gut hormones and insulin resistance in animal models with limited trials in human. Supplementation with probiotic has also been shown not only affect glucose homeostasis, but improved other diabetes related comorbidities such as obesity, hypertension, and hyperlipidemia. Objectives and hypotheses: To address this research gap, this Randomized Controlled Trial (RCT) is proposed to determine the efficacy of probiotic supplementations as adjuvant therapy to improve glucose homeostasis through modulating gut microbiota composition and gut hormones secretion in individuals with type 2 diabetes. We hypothesized that the probiotic supplementations will improve blood glucose control as well as other diabetes related co-morbidities in individuals with type 2 diabetes. Methodology: This is a double blind randomized parallel group control trial with 3 months probiotic supplementation or placebo. After screening the eligible subjects will be selected. Then, after consent taking, subjects will be randomly assigned to either receive probiotic or supplement for 3 months. Measurements of blood parameters including glycemic control related parameters, lipid profile, renal profile, and liver function tests as well as three day diet recall, and anthropometry measurements will take place at baseline, after 6 weeks and after 12 months. Expected Outcomes: Probiotic supplementation as an adjuvant therapy would improve glucose homeostasis and gut health as compared to the placebo and eventually will beneficially affect other diabetes related conditions. This study would provide avenue to identify the possibility of probiotic supplementations as an adjuvant therapy in the management of type 2 diabetes.

NCT ID: NCT01735149 Recruiting - Hyperlipidemia Clinical Trials

Efficacy and Safety of Kochujang Pills on Improvement of Blood Lipids

Start date: November 2012
Phase: Phase 2/Phase 3
Study type: Interventional

The investigators performed a 12-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Kochujang pills on improvement of blood lipids. The investigators measured improvement of blood lipids parameters , including Total Cholesterol, LDL-C, Triglyceride and HDL-C, and monitored their blood pressure.

NCT ID: NCT01382277 Recruiting - Clinical trials for Coronary Artery Disease

Rosuvastatin Effect on Reducing Coronary Atherosclerosis Plaques Volume

REDUCT
Start date: March 2011
Phase: Phase 4
Study type: Interventional

This multicentre, open-label, single-arm Study is to evaluate the effect of Rosuvastatin 20 mg 76 weeks on coronary atherosclerosis plaque versus baseline in Chinese coronary heart disease (CHD) patients with hyperlipidemia by measuring the plaque volume using a 64 slice spiral CT. Effect on blood lipids, hsCRP and Carotid intima-media thickness (CIMT) is also evaluated.

NCT ID: NCT01265160 Recruiting - Hyperlipidemia Clinical Trials

Jiangzhuo Prescription ,Fenofibrate and Placebo in the Treatment of Hyperlipidemia (Syndrome of Phlegm Obstruction)Clinical Study (JZF)

JZF
Start date: November 2010
Phase: N/A
Study type: Observational

Jiangzhuo prescription ,fenofibrate and placebo in the treatment of hyperlipidemia(syndrome of phlegm obstruction), randomized, parallel-controlled, multi-center clinical study